Cross Country Healthcares, Inc’s filing revealed that its Director CASH W LARRY acquired Company’s shares for reported $40829.0 on Dec 09 ’25. In the deal valued at $8.17 per share,5,000 shares were bought. As a result of this transaction, CASH W LARRY now holds 204,632 shares worth roughly $1.63 million.
Citizens JMP upgraded its Cross Country Healthcares, Inc [CCRN] rating to a Mkt outperform from a a Mkt perform in a research note published recently. A number of analysts have revised their coverage, including Barrington Research’s analysts, who decreased its forecast for the stock in early December from “an Outperform” to “a Mkt perform”. JMP Securities began covering CCRN with “Mkt perform” recommendation on December 06, 2023. Jefferies revised its rating on November 03, 2023. It rated CCRN as “a Hold” which previously was an “a Buy”.
Price Performance Review of CCRN
On Tuesday, Cross Country Healthcares, Inc [NASDAQ:CCRN] saw its stock fall -2.33% to $7.95. Over the last five days, the stock has lost -21.05%. Cross Country Healthcares, Inc shares have fallen nearly -56.00% since the year began. Nevertheless, the stocks have fallen -56.22% over the past one year. While a 52-week high of $18.30 was reached on 01/24/25, a 52-week low of $7.43 was recorded on 12/04/25.
Levels Of Support And Resistance For CCRN Stock
The 24-hour chart illustrates a support level at 7.72, which if violated will result in even more drops to 7.48. On the upside, there is a resistance level at 8.18. A further resistance level may holdings at 8.40.
How much short interest is there in Cross Country Healthcares, Inc?
A steep rise in short interest was recorded in Cross Country Healthcares, Inc stocks on 2025-11-14, growing by 0.65 million shares to a total of 3.36 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 2.7 million shares. There was a rise of 19.43%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 26, 2023 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating.
